The purpose of the Informatics Core Facility in the MSKCC SPORE in Prostate Cancer is to provide information technology and data modeling that will facilitate the translation of scientific discovery to clinical care. Although this process may occur in a variety of mechanisms, certain activities dominate. Because markers of disease may be discovered, this Core Facility would be needed in helping to define their clinical role. Groups of markers may need optimal assembly for the purposes of clinical prediction. Complex clinical decisions may require formal analysis. Large amounts of data may need thoughtful simplification and processing. Limited resources may need rational allocation. Each of these activities may utilize the Informatics Core Facility; it is, there fore, important that this Facility provides a quality program of innovative collaborations supporting basic and clinical research. Moreover, members of the Core Facility will function as colleagues with SPORE scientists and clinicians throughout the research process.
Specific Aims : l) To perform detailed prognostic modeling, such as nomogram development. 2) To develop decision analytic systems which address important clinical problems. 3) To provide statistical analysis of data, to address hypothesis of interest, from personnel dedicated to prostate cancer. 4) To ensure rational resource allocation by statistical power analysis for all requests of specimens and mice. 5) To provide investigators with high-quality datasets by: a. extracting patient data from various Memorial Sloan-Kettering Cancer Center databases b. actively following patients, who do not return to MSKCC, through letters and phone calls, and storing this data in databases we develop. c. applying sophisticated algorithms to consistently select and compute critical dataset fields (e.g., failure dates). d. working with institutional database developers to ensure that prostate cancer data are being stored and collected in a manner conducive to both research and clinical care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092629-02
Application #
6656472
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-10
Project End
2003-08-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Hugosson, Jonas; Godtman, Rebecka Arnsrud; Carlsson, Sigrid V et al. (2018) Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol 52:27-37
Kohestani, Kimia; Chilov, Marina; Carlsson, Sigrid V (2018) Prostate cancer screening-when to start and how to screen? Transl Androl Urol 7:34-45
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Kim, Kwanghee; Watson, Philip A; Lebdai, Souhil et al. (2018) Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts. Clin Cancer Res 24:2408-2416
Assel, Melissa J; Gerdtsson, Axel; Thorek, Daniel L J et al. (2018) Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project. Oncotarget 9:5778-5785
Ran, Leili; Chen, Yuedan; Sher, Jessica et al. (2018) FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor. Cancer Discov 8:234-251
Kinsella, Netty; Stattin, Pär; Cahill, Declan et al. (2018) Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. Eur Urol 74:261-280
Li, Weiqiang; Middha, Mridu; Bicak, Mesude et al. (2018) Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. Eur Urol 74:710-719
Aras, Omer; Pearce, Gillian; Watkins, Adam J et al. (2018) An in-vivo pilot study into the effects of FDG-mNP in cancer in mice. PLoS One 13:e0202482
Sjoberg, Daniel D; Vickers, Andrew J; Assel, Melissa et al. (2018) Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. Eur Urol 73:941-948

Showing the most recent 10 out of 505 publications